The level of endotoxemia in sepsis varies in relation to the underlying infection: Impact on final outcome

Immunology Letters

Volumn 152, Issue 2, 2013, Pages 167-172

  Kritselis, Ioannis ^a   Tzanetakou, Vassiliki ^b   Adamis, Georgios ^c   Anthopoulos, George ^d   Antoniadou, Eleni ^c   Bristianou, Magdalini ^e   Kotanidou, Anastasia ^b   Lignos, Michail ^b   Polyzos, Kostantinos ^f   Retsas, Theodoros ^b   Sassopoulou, Panagiota ^g   Papaioannou, Andrianna I ^h   Sinapidis, Dimitrios ^f   Sereti, Kalliopi ^h   Vittoros, Vasileios ⁱ   Ghanas, Panagiotis ^a   Gogos, Charalambos ^j   Giamarellos Bourboulis, Evangelos J ^b  

^a Nafplion General Hospital   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

^e General Hospital of Lamia   (Greece)

^f UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^g Intensive Care Unit Bodosakis General Hospital   (Greece)

^h SISMANOGLIO HOSPITAL   (Greece)

ⁱ Thriasion Elefsis General Hospital   (Greece)

^j UNIVERSITY OF PATRAS   (Greece)

more..

Author keywords

Endotoxins; Monocytes; Outcome; Sepsis

Indexed keywords

ANTIINFECTIVE AGENT; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL INFECTION; ACUTE CHOLECYSTITIS; ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD SAMPLING; CELL ISOLATION; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTOXEMIA; ENZYME IMMUNOASSAY; EX VIVO STUDY; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOPATHOGENESIS; INCUBATION TIME; INFECTION; INFLAMMATION; INNATE IMMUNITY; KINETICS; LIMULUS LYSATE TEST; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEPSIS; SHOCK; SUPERNATANT; SURVIVOR; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; BLOOD; CLINICAL TRIAL; GRAM NEGATIVE INFECTION; IMMUNOLOGY; MONONUCLEAR CELL; PNEUMONIA;

AGED; ENDOTOXEMIA; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; PNEUMONIA; PROSPECTIVE STUDIES; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879749997     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.05.013     Document Type: Article

References (34)

1. Dombrovskiy V.Y., Martin A.A., Sunderram J., Paz H.L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244-1250.
2. Tsujimoto H., Ono S., Mochizuki H. Role of translocation of pathogen-associated molecular patterns in sepsis. Dig Surg 2009, 26:100-109.
3. Ding J.L., Ho B. Endotoxin detection-from limulus amebocyte lysate to recombinant factor C. Subcell Biochem 2010, 53:187-208.
4. Marshall J.C., Foster D., Vincent J.L., Cook D.J., Cohen J., Dellinger R.P., et al. MEDIC study: diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004, 90:527-534.
5. Cohen J. Non-antibiotic strategies for sepsis. Clin Microbiol Infect 2009, 15:302-307.
6. Marshall J.C. Endotoxin in the pathogenesis of sepsis. Contrib Nephrol 2010, 167:1-13.
7. Rice T.W., Wheeler A.P., Bernard G.R., Vincent J.L., Angus D.C., Aikawa N., et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010, 38:1685-1694.
8. Bloomberg. Eisai's sepsis drug Eritoran fails to save more lives in final-stage study. [Posted 25.01.11; accessed 2.01.13]. http://www.bloomberg.com/news/2011-01-25/eisai-s-sepsis-drug-eritoran-fails-to-save-more-lives-in-final-stage-study.html.
9. Ranieri V.M., Thompson B.T., Barie P.S., Dhainaut J.F., Douglas I.S., Finfer S., et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064.
10. Gogos C., Kotsaki A., Pelekanou A., Giannikopoulos G., Vaki I., Maravitsa P., et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 2010, 14:R96.
11. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-1256.
12. Pinson A.G., Philbrick J.T., Lindbeck G.H., Schorling J.B. Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med 1997, 15:148-151.
13. Calandra T., Cohen J. The international sepsis forum consensus definitions of infections in the intensive care unit. Crit Care Med 2005, 33:1639-1648.
14. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
15. Rittisch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-786.
16. Danner R.L., Elin R.J., Hosseini J.M., Wesley R.A., Reilly J.M., Parillo J.E. Endotoxemia in human septic shock. Chest 1991, 99:169-175.
17. Casey L.C., Balk R.A., Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993, 119:771-778.
18. Guidet B., Barakett V., Vassal T., Petit J.C., Offenstadt G. Endotoxemia and bacteremia in patients with sepsis syndrome in the intensive care unit. Chest 1994, 106:1194-1201.
19. Bates D.W., Parsonnet J., Ketchum P.A., Miller E.B., Novitsky T.J., Sands K., et al. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. Clin Infect Dis 1998, 27:582-591.
20. Poukoulidou T., Spyridaki A., Mihailidou I., Kopterides P., Pistiki A., Alexiou Z., et al. TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the complicated pathogen. BMC Infect Dis 2011, 11:309.
21. File T.M. Community-acquired pneumonia. Lancet 2003, 362:1991-2001.
22. Cohen J. The detection and interpretation of endotoxaemia. Intensive Care Med 2000, 26:S51-S56.
23. van Langevelde P., Joop K., van Loon J., Frölich M., Groeneveld P.H., Westendorp R.G., et al. Endotoxin, cytokines and procalcitonin in febrile patients admitted to the hospital: identification of subjects at high risk of mortality. Clin Infect Dis 2000, 31:1343-1348.
24. Opal S.M., Scannon P.J., Vincent J.L., White M., Carroll S.F., Palardy J., et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein inpatients with severe sepsis and septic shock. J Infect Dis 1999, 180:1584-1589.
25. Marshall J.C., Walker P.M., Foster D.M., Harris D., Ribeiro M., Paice J., et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 2002, 6:343-348.
26. Giamarellos-Bourboulis E.J., van de Veerdonk F.L., Mouktaroudi M., Raftogiannis M., Antonopoulou A., Joosten L.A., et al. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit Care 2011, 15:R27.
27. Boomer J.S., To K., Chang K.C., Takasu O., Obsorne D.F., Walton A.H., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. J Am Med Assoc 2011, 306:2594-2605.
28. Spyridaki A., Raftogiannis M., Antonopoulou A., Tsaganos T., Routsi C., Baziaka F., et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother 2012, 56:3819-3825.
29. West M.A., Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002, 30:S64-S73.
30. Cavaillon J.M., Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006, 10:233.
31. Giamarellos-Bourboulis E.J., Perdios J., Lelekis M., Eoconomou E., Tsouroulas P., Giamarellou H. Impact of cefuroxime administration on endotoxin (LPS) and tumour necrosis factor-a (TNFa) blood levels in patients suffering from acute pyelonephrits: a preliminary report. Int J Antimicrob Agents 1999, 11:115-119.
32. Giamarellos-Bourboulis E.J., Nikou G.C., Matsaggoura M., Toumpanakis C., Grecka P., Giannikopoulos G., et al. Alterations of systemic endotoxaemia over the course of acute oedematous pancreatitis. Correlation to the advent of an infection?. Pancreatology 2003, 3:323-328.
33. Matsumoto N., Takahashi G., Kojika M., Suzuki Y., Inoue Y., Inada K., et al. Interleukin-8 induces an elevation in the endotoxin activity assay (EAA) level: does the EAA truly measure the endotoxin level?. J Infect Chemother 2013, March 5 [Epub ahead of print].
34. Romaschin A.D., Klein D.J., Marshall J.C. Bench-to-bedside review: clinical experience with the endotoxin activity assay. Crit Care 2012, 16:248.